Comparison of the effects of sibutramine and other weight-modifying drugs on extracellular dopamine in the nucleus accumbens of freely moving rats

Toshihito Suzuki, Shuzo Abe, Mika Yamaguchi, Atsuomi Baba, Takafumi Hori, Hiroyasu Shiraishi, Takehiko Ito

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The acute effects of systemic administration of the anti-obesity agent sibutramine on extracellular dopamine (DA) in the nucleus accumbens of freely moving rats were studied using in vivo microdialysis and compared with the actions of phentermine and d-amphetamine at doses 1x and 3x their respective 2 h ED50 values to reduce food intake in rats. At the lower dose, sibutramine did not elevate extracellular DA concentrations; however, at the higher dose (6.0 mg kg-1, i.p.) it caused a modest and prolonged increase in extraneuronal DA. A maximal rise was observed at 60 min post-sibutramine treatment (+231% compared to controls) with DA levels remaining elevated for up to 160 min post treatment. In contrast, phentermine and d-amphetamine significantly enhanced DA efflux at both the lower and higher doses. These elevations of DA levels were significantly greater than that seen with the corresponding dose of sibutramine over 0-80 min post treatment. Maximal rises in DA levels resulting from the higher dose of each drug were +733% (phentermine, 3.9 mg kg-1, i.p.) and +603% (d-amphetamine, 1.5 mg kg-1, i.p.) compared to controls 40 min post treatment. The highest doses of phentermine and d-amphetamine increased rat locomotor activity up to 100 min and 160 min post treatment, respectively, whereas the equivalent sibutramine dose had no effect. These findings therefore suggest that dopaminergic reward mechanisms are not involved in the reduction of food intake by sibutramine. Furthermore, they are consistent with the view that sibutramine lacks abuse potential. (C) 2000 Wiley-Liss, Inc.

Original languageEnglish
Pages (from-to)167-176
Number of pages10
JournalSynapse
Volume38
Issue number2
DOIs
Publication statusPublished - 2000

Fingerprint

sibutramine
Nucleus Accumbens
Phentermine
Dopamine
Dextroamphetamine
Weights and Measures
Pharmaceutical Preparations
Eating
Anti-Obesity Agents
Microdialysis
Locomotion
Reward

Keywords

  • Dopamine
  • In vivo microdialysis
  • Nucleus accumbens
  • Sibutramine
  • Weight-reducing drugs

ASJC Scopus subject areas

  • Neuroscience(all)
  • Physiology
  • Pharmacology

Cite this

Comparison of the effects of sibutramine and other weight-modifying drugs on extracellular dopamine in the nucleus accumbens of freely moving rats. / Suzuki, Toshihito; Abe, Shuzo; Yamaguchi, Mika; Baba, Atsuomi; Hori, Takafumi; Shiraishi, Hiroyasu; Ito, Takehiko.

In: Synapse, Vol. 38, No. 2, 2000, p. 167-176.

Research output: Contribution to journalArticle

Suzuki, Toshihito ; Abe, Shuzo ; Yamaguchi, Mika ; Baba, Atsuomi ; Hori, Takafumi ; Shiraishi, Hiroyasu ; Ito, Takehiko. / Comparison of the effects of sibutramine and other weight-modifying drugs on extracellular dopamine in the nucleus accumbens of freely moving rats. In: Synapse. 2000 ; Vol. 38, No. 2. pp. 167-176.
@article{5a6534e074504170b161dfb875e97b74,
title = "Comparison of the effects of sibutramine and other weight-modifying drugs on extracellular dopamine in the nucleus accumbens of freely moving rats",
abstract = "The acute effects of systemic administration of the anti-obesity agent sibutramine on extracellular dopamine (DA) in the nucleus accumbens of freely moving rats were studied using in vivo microdialysis and compared with the actions of phentermine and d-amphetamine at doses 1x and 3x their respective 2 h ED50 values to reduce food intake in rats. At the lower dose, sibutramine did not elevate extracellular DA concentrations; however, at the higher dose (6.0 mg kg-1, i.p.) it caused a modest and prolonged increase in extraneuronal DA. A maximal rise was observed at 60 min post-sibutramine treatment (+231{\%} compared to controls) with DA levels remaining elevated for up to 160 min post treatment. In contrast, phentermine and d-amphetamine significantly enhanced DA efflux at both the lower and higher doses. These elevations of DA levels were significantly greater than that seen with the corresponding dose of sibutramine over 0-80 min post treatment. Maximal rises in DA levels resulting from the higher dose of each drug were +733{\%} (phentermine, 3.9 mg kg-1, i.p.) and +603{\%} (d-amphetamine, 1.5 mg kg-1, i.p.) compared to controls 40 min post treatment. The highest doses of phentermine and d-amphetamine increased rat locomotor activity up to 100 min and 160 min post treatment, respectively, whereas the equivalent sibutramine dose had no effect. These findings therefore suggest that dopaminergic reward mechanisms are not involved in the reduction of food intake by sibutramine. Furthermore, they are consistent with the view that sibutramine lacks abuse potential. (C) 2000 Wiley-Liss, Inc.",
keywords = "Dopamine, In vivo microdialysis, Nucleus accumbens, Sibutramine, Weight-reducing drugs",
author = "Toshihito Suzuki and Shuzo Abe and Mika Yamaguchi and Atsuomi Baba and Takafumi Hori and Hiroyasu Shiraishi and Takehiko Ito",
year = "2000",
doi = "10.1002/1098-2396(200011)38:2<167::AID-SYN8>3.0.CO;2-W",
language = "English",
volume = "38",
pages = "167--176",
journal = "Synapse",
issn = "0887-4476",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Comparison of the effects of sibutramine and other weight-modifying drugs on extracellular dopamine in the nucleus accumbens of freely moving rats

AU - Suzuki, Toshihito

AU - Abe, Shuzo

AU - Yamaguchi, Mika

AU - Baba, Atsuomi

AU - Hori, Takafumi

AU - Shiraishi, Hiroyasu

AU - Ito, Takehiko

PY - 2000

Y1 - 2000

N2 - The acute effects of systemic administration of the anti-obesity agent sibutramine on extracellular dopamine (DA) in the nucleus accumbens of freely moving rats were studied using in vivo microdialysis and compared with the actions of phentermine and d-amphetamine at doses 1x and 3x their respective 2 h ED50 values to reduce food intake in rats. At the lower dose, sibutramine did not elevate extracellular DA concentrations; however, at the higher dose (6.0 mg kg-1, i.p.) it caused a modest and prolonged increase in extraneuronal DA. A maximal rise was observed at 60 min post-sibutramine treatment (+231% compared to controls) with DA levels remaining elevated for up to 160 min post treatment. In contrast, phentermine and d-amphetamine significantly enhanced DA efflux at both the lower and higher doses. These elevations of DA levels were significantly greater than that seen with the corresponding dose of sibutramine over 0-80 min post treatment. Maximal rises in DA levels resulting from the higher dose of each drug were +733% (phentermine, 3.9 mg kg-1, i.p.) and +603% (d-amphetamine, 1.5 mg kg-1, i.p.) compared to controls 40 min post treatment. The highest doses of phentermine and d-amphetamine increased rat locomotor activity up to 100 min and 160 min post treatment, respectively, whereas the equivalent sibutramine dose had no effect. These findings therefore suggest that dopaminergic reward mechanisms are not involved in the reduction of food intake by sibutramine. Furthermore, they are consistent with the view that sibutramine lacks abuse potential. (C) 2000 Wiley-Liss, Inc.

AB - The acute effects of systemic administration of the anti-obesity agent sibutramine on extracellular dopamine (DA) in the nucleus accumbens of freely moving rats were studied using in vivo microdialysis and compared with the actions of phentermine and d-amphetamine at doses 1x and 3x their respective 2 h ED50 values to reduce food intake in rats. At the lower dose, sibutramine did not elevate extracellular DA concentrations; however, at the higher dose (6.0 mg kg-1, i.p.) it caused a modest and prolonged increase in extraneuronal DA. A maximal rise was observed at 60 min post-sibutramine treatment (+231% compared to controls) with DA levels remaining elevated for up to 160 min post treatment. In contrast, phentermine and d-amphetamine significantly enhanced DA efflux at both the lower and higher doses. These elevations of DA levels were significantly greater than that seen with the corresponding dose of sibutramine over 0-80 min post treatment. Maximal rises in DA levels resulting from the higher dose of each drug were +733% (phentermine, 3.9 mg kg-1, i.p.) and +603% (d-amphetamine, 1.5 mg kg-1, i.p.) compared to controls 40 min post treatment. The highest doses of phentermine and d-amphetamine increased rat locomotor activity up to 100 min and 160 min post treatment, respectively, whereas the equivalent sibutramine dose had no effect. These findings therefore suggest that dopaminergic reward mechanisms are not involved in the reduction of food intake by sibutramine. Furthermore, they are consistent with the view that sibutramine lacks abuse potential. (C) 2000 Wiley-Liss, Inc.

KW - Dopamine

KW - In vivo microdialysis

KW - Nucleus accumbens

KW - Sibutramine

KW - Weight-reducing drugs

UR - http://www.scopus.com/inward/record.url?scp=0033775196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033775196&partnerID=8YFLogxK

U2 - 10.1002/1098-2396(200011)38:2<167::AID-SYN8>3.0.CO;2-W

DO - 10.1002/1098-2396(200011)38:2<167::AID-SYN8>3.0.CO;2-W

M3 - Article

C2 - 11018791

AN - SCOPUS:0033775196

VL - 38

SP - 167

EP - 176

JO - Synapse

JF - Synapse

SN - 0887-4476

IS - 2

ER -